Chapter 7 – Pharmacological Treatment

Objectives

The treatment of AH is ultimately aimed at reducing CV morbidity and mortality. Clinical studies of outcome have provided scientific evidence of the benefits of the use of diuretics (DIUs) (GR: I; LE: A)\(^{5,10-15}\) beta-blockers (BBs) (GR: I; LE: A)\(^{10-13,16}\) calcium-channel blockers (CCBs) (GR: I; LE: A)\(^{10,11,15,17,21}\) angiotensin-converting-enzyme inhibitors (ACEIs) (GR: I; LE: A)\(^{10,11,15,17,24-26}\) and angiotensin-receptor blockers (ARBs) (GR: I; LE: A)\(^{10,11,27-33}\). It is worth noting that most of those studies have used an association of drugs. Based on the information available, the protection observed does not depend on the type of drug used, but mainly on BP reduction.\(^{10,11,34}\) Recent meta-analyses have reported that the benefits obtained from BB are smaller\(^{10,11,35-37}\) as compared to those provided by the other drug groups, and, thus, BBs should be reserved for specific situations. Regarding alpha-blockers and direct vasodilators, there is no effective information on the outcomes of morbidity and mortality. Regarding direct renin inhibitors, only one study of outcome in diabetic patients has been early interrupted due to lack of benefits and possible harm.\(^{38}\) The higher the CV risk, the greater the benefits, which occur even for small BP elevations.\(^{3,4,8,9,39}\)

General principles of the pharmacological treatment

When pharmacological treatment is indicated, the patient should be instructed about the importance of its continuity, the occasional need for dose adjustment and change or association of drugs, and the occasional appearance of adverse effects.

For one medicine to be indicated, it should preferably:

- have shown the ability to reduce CV morbidity and mortality;
- be effective orally;
- be well tolerated;
- be taken the fewest possible times per day;
- be started at the smallest effective doses;
- be able to be used in association;
- be used for at least four weeks, before any change, except for special situations;
- have quality control in its production.

Choice of the medication

All antihypertensive drugs available can be used if specific indications and contraindications are observed (Table 1). The initial preference is always for those with confirmed action in decreasing CV events, being the others reserved for special cases that require the association of multiple drugs to achieve BP targets.

General characteristics of antihypertensive drugs

Diuretics

The mechanisms of antihypertensive action of DIUs are initially related to their natriuretic effects, with a decrease in the extracellular volume. After 4-6 weeks, the circulating volume normalizes and a reduction in peripheral vascular resistance (PVR) occurs. Diuretics reduce BP and CV morbidity and mortality.\(^{10,12,14}\) Their antihypertensive effect is not directly related to their doses, but the side effects are.

Thiazide or similar DIUs (chlorthalidone, hydrochlorothiazide and indapamide) at low doses should be preferred, because they are milder and have a longer time of action. Loop DIUs (furosemide and bumetanide) should be reserved for cases of renal failure (creatinine > 2.0 mg/dl or estimated GFR < 30 mL/min/1.73m\(^2\)) and edema (HF or renal failure). Potassium-sparing DIUs (spironolactone and amiloride) are usually associated with a thiazide or loop DIU.

Adverse effects

Their major adverse effects are weakness, cramps, hypovolemia and erectile dysfunction. From the metabolic viewpoint, hypopotassemia is the most common, occasionally accompanied by hypomagnesemia, which can induce ventricular arrhythmias, mainly extrasystole. Diuretics can cause glucose intolerance by reducing insulin release, increasing the risk for type 2 DM. Uric acid increase is an almost universal effect of DIUs, of undocumented clinical consequences, except for triggering gout crises in predisposed individuals. The use of low doses decreases the risk for adverse effects, without hindering the antihypertensive efficacy, especially when associated with other drug classes. Spironolactone can cause hyperpotassemia, particularly in patients with impaired renal function.

Central action agents

Alpha-agonists of central action stimulate alpha-2 receptors involved in sympatho-inhibitory mechanisms.\(^{40}\) Not all alpha-agonists of central action are selective. Their well-defined effects are as follows: a decrease in sympathetic activity and reflex of baroreceptors, contributing to relative bradycardia and postural hypotension; mild decrease in PVR and cardiac output; a reduction in serum levels of renin; and fluid retention.

Some representatives of that group are: methyldopa, clonidine, guanabenz and inhibitors of imidazoline receptors (moxonidine and rilmenidine).\(^{41}\)

### Table 1 – Antihypertensive drugs available

| Antihypertensive Drugs Available | Global Recommendation (GR) | Local Expert Opinion (LE) |
|----------------------------------|-----------------------------|---------------------------|
| DIUs (GR: I; LE: A)              |                             |                           |
| adrenergic inhibitors            |                             |                           |
| Central action – central alpha-2 agonists (GR: IIb; LE: C) |                             |                           |
| BBs – beta adrenergic blockers (GR: I; LE: A) |                             |                           |
| Alpha-blockers – alpha-1 adrenergic blockers (GR: IIb; LE: C) |                             |                           |
| Direct vasodilators (GR: IIb; LE: C) |                             |                           |
| CCBs (GR: I; LE: A)             |                             |                           |
| ACEIs (GR: I; LE: A)            |                             |                           |
| ARBs (GR: I; LE: A)             |                             |                           |
| Direct renin inhibitors (GR: IIb; LE: C) |                             |                           |
Clonidine can be useful in hypertensive situations associated with: restless legs syndrome,\textsuperscript{42} withdrawal of opioids,\textsuperscript{43} menopausal hot flushes,\textsuperscript{44} diarrhea associated with diabetic neuropathy,\textsuperscript{45} and sympathetic hyperactivity of patients with alcoholic cirrhosis.\textsuperscript{46} These drugs have no unwanted metabolic effect, because they interfere with neither peripheral resistance to insulin nor lipid profile.

**Adverse effects**

Methyldopa can cause autoimmune reactions, such as fever, hemolytic anemia, galactorrhea and liver dysfunction, which, in most cases, disappear with use cessation. If an adverse reaction occurs, it can be replaced by another central alpha-agonist.\textsuperscript{41} Clonidine has a higher risk for the rebound effect with discontinuation, especially when associated with a BB, and can be dangerous in the preoperative period.\textsuperscript{40} The drugs in this class have adverse reactions due to their central action, such as drowsiness, sedation, dry mouth, fatigue, postural hypotension, and erectile dysfunction.\textsuperscript{40,41}

**Beta-blockers**

Beta-blockers promote initial decrease in cardiac output and renin secretion, with readaptation of baroreceptors and decrease in catecholamines in nervous synapses.\textsuperscript{47,48} In addition to such actions, third-generation drugs (carvedilol, nebivolol) have a vasodilating effect via different mechanisms: carvedilol, via concomitant blockade of alpha-1 adrenergic receptor,\textsuperscript{47-50} and nebivolol, by increasing nitric oxide synthesis and release on the vascular endothelium.\textsuperscript{47,48,50} Propranolol is useful to patients with essential tremor, hyperkinetic syndromes, vascular headache and portal hypertension.\textsuperscript{47,48}

**Adverse effects**

They consist of bronchospasm, bradycardia, atrioventricular conduction disorders, peripheral vasostenosis, insomnia, nightmares, psychic depression, asthenia and sexual dysfunction. First- and second-generation BBs are formally contraindicated to patients with bronchial asthma, chronic obstructive pulmonary disease (COPD) and second- and third-degree ativoventricular blocks. They can cause glucose intolerance, induce new cases of DM, and lead to hypertriglyceridemia with LDL-cholesterol elevation and HDL-cholesterol reduction. The impact on glucose metabolism is potentiated when combined with DIUs. Third-generation BBs (carvedilol and nebivolol) have neutral impact or can even improve the glucose and lipid metabolism, possibly because of the vasodilating effect with decrease in insulin resistance and improvement of glucose uptake by peripheral tissues.\textsuperscript{47,50} Studies on nebivolol have shown less sexual dysfunction, possibly because of the effect on endothelial nitric oxide synthesis.\textsuperscript{47,50}

**Alpha-blockers**

Alpha-blockers act as competitive antagonists of postsynaptic alpha-1 receptors, leading to a reduction in PVR without major changes in cardiac output.\textsuperscript{41} Some representatives of this drug class are doxazosin, prazosin and terazosin. The hypotensive effect is mild in monotherapy, the combined use being preferred. They have a favorable and discrete action on the lipid and glucose metabolisms, especially improving the symptoms related to benign prostate hypertrophy.\textsuperscript{41}

**Adverse effects**

Alpha-blockers can cause symptomatic hypotension on the first dose. The phenomenon of tolerance is frequent, requiring increasing doses. Women can have urine incontinence. There is evidence that patients treated with doxazosin are at higher risk for CHF.\textsuperscript{41}

**Direct acting vasodilators**

Representatives of this drug class are hydralazine and minoxidil. They act directly, relaxing arterial smooth muscle, leading to a PVR reduction.\textsuperscript{40}

**Adverse effects**

The side effects of hydralazine are headache, flushing, reflex tachycardia and lupus-like reaction (dose-dependent).\textsuperscript{41} Hydralazine should be used carefully in patients with CAD, and avoided in those with dissecting aortic aneurysm and a recent cerebral hemorrhage episode. In addition, it can cause anorexia, nausea, vomiting and diarrhea. A common side effect of minoxidil is hirsutism, in approximately 80% of the patients. A less common side effect is the general expansion of the circulating volume and reflex tachycardia.

**Calcium-channel blockers**

Calcium channel blockers cause a reduction in PVR, because of the decreased calcium amount inside arteriolar smooth muscle cells, due to calcium channel blockade in their membranes.\textsuperscript{55} They are classified as dihydropyridine and nondihydropyridine CCBs.

Dihydropyridine CCBs (amlodipine, nifedipine, felodipine, nitrendipine, manidipine, lercanidipine, levamlodipine, lacidipine, isradipine, nisoldipine, nimodipine) have mainly a vasodilating effect, with minimum interference in HR and systolic function, being, thus, more often used as antihypertensive agents. Nondihydropyridine CCBs, such as phenylalkylamines (verapamil) and benzothiazepines (diltiazem), have a lower vasodilating effect, can cause bradycardia and have an antiarrhythmic effect, which limit their use to specific cases. Nondihydropyridine CCBs can depress the systolic function, mainly in patients with systolic dysfunction prior to their use, and, thus, should be avoided in that condition. Long-acting CCBs should be preferred to prevent unwanted oscillations in HR and BP. They are effective antihypertensive drugs that reduce CV morbidity and mortality.\textsuperscript{52-55} A study of outcome has reassured the efficacy, tolerability and safety of this drug class for the AH treatment of patients with CAD,\textsuperscript{56} being an alternative when BBs cannot be used, or even in association, in cases of refractory angina.
Adverse effects

Ankle swelling is usually the most common side effect, resulting from the vasodilating action (more arterial than venous), which causes capillary transudation. Throbbing headache and dizziness are not uncommon. Facial blushing is more common with fast-acting dihydropyridine CCBs. Hyperchromia of the distal third of the legs (ochre dermatitis) and gingival hypertrophy might occur. Such effects can be dose-dependent. Verapamil and diltiazem can worsen HF, bradycardia and atrioventricular block. Constipation is observed with verapamil.  

Angiotensin-converting-enzyme inhibitors

Angiotensin-converting-enzyme inhibitors are effective antihypertensive drugs whose major action is inhibition of angiotensin-converting-enzyme, hindering transformation of angiotensin I into angiotensin II, a vasoconstrictor. They are effective to treat AH, reducing CV morbidity and mortality. They are useful in many other CV conditions, such as HF with reduced ejection fraction, post-infarction anti-remodeling, and might have antiatherosclerotic properties. They delay renal function decline in patients with diabetic nephropathy or nephropathy of other etiologies.  

Adverse effects

Usually well-tolerated by most hypertensive patients, dry cough is their major side effect, affecting 5-20% of patients. Angioneurotic edema and skin rash are rare. Serum urea and creatinine elevation, usually small and reversible, is a transient phenomenon observed in the initial use of ACEIs in patients with renal failure. In the long run, ACEIs are effective to halt the progression of CKD. They can cause hyperpotassemia in patients with renal failure, mainly those with DM. They can reduce GFR and increase the levels of urea, creatinine and potassium in patients with bilateral stenosis of the renal arteries or renal artery stenosis in a single functioning kidney. They are contraindicated during pregnancy, because of the risk of fetal complications. Thus, they should be carefully used and often monitored in adolescents and childbearing-age women.  

Angiotensin II AT1 receptor blockers

The ARBs antagonize the action of angiotensin II via the specific blockade of AT1 receptors, responsible for angiotensin II own actions of vasoconstriction, proliferation and stimulation of aldosterone release. In the AH treatment, especially of populations at high CV risk or with comorbidities, ARBs reduce CV and renal (diabetic nephropathy) morbidity and mortality.  

Adverse effects

Adverse effects related to ARBs are not common, exanthema being rarely observed. Similarly to ACEIs, ARBs are contraindicated during pregnancy, and the same care should be taken for childbearing-age women.  

Direct renin inhibitors

Aliskiren, the only representative of this drug class available for clinical use, causes direct renin inhibition with consequent decrease in angiotensin II production. Other actions might contribute to BP lowering and tissue protection, such as the reduction in renin plasma activity, the blockade of a renin/prorenin receptor, and the decrease in intracellular angiotensin II production. Studies of antihypertensive efficacy have confirmed its ability in monotherapy to lower BP in an intensity similar to that of other antihypertensive drugs. There is, however, no evidence of its benefits on morbidity and mortality.  

Adverse effects

They are well tolerated. Skin rash, diarrhea (especially at high doses (> 300 mg/day)), CPK increase, and cough are the most frequent events, whose incidence is usually < 1%. Their use is contraindicated during pregnancy.  

The beginning of pharmacological treatment

Pharmacological treatment is indicated for individuals with stage 1 AH and at low and intermediate CV risk, when nonpharmacological measures proved ineffective after an initial period of at least 90 days. In especial situations, in which access and/or return to medical care is difficult, the initial use of antihypertensive drugs, even for that group of patients, might be considered. For individuals with stage 1 AH and at high CV risk or with established CVD, the use of antihypertensive agents should be started immediately. Likewise, for patients with stage 2 and 3 AH, regardless of the CV risk, pharmacological treatment should be started immediately. For prehypertensive individuals, pharmacological treatment might be an option, considering the CV risk and/or presence of CVD. For 60- to 79-year-old patients with SBP ≥ 140 mm Hg and those ≥ 80 years with SBP ≥ 160 mm Hg, pharmacological therapy should begin earlier.  

Therapeutic schemes

The pharmacological treatment can be performed with one or more drug classes, as required, to meet the BP targets and according to specific situations (Figure 1).  

Monotherapy

Monotherapy can be the initial antihypertensive strategy for stage 1 AH patients at low and intermediate CV risk. However, depending on the BP target to be achieved, most patients will require drug combination. The treatment should be individualized, and the initial choice of drug to be used as monotherapy should be based on the following aspects: ability to lower CV morbidity and mortality; predominant pathophysiological mechanism in the patient to be treated; individual characteristics; associated diseases; and socioeconomic conditions.  

Based on those criteria, the classes of antihypertensive drugs currently preferred for BP control in the initial monotherapy are as follows (Figures 1 and 2):

- Thiazide DIUs (preference for chlorthalidone) 5,9-15,39,71,72
- ACEIs 7-11,15,17,18,24-26
- CCBs 7-11,15,17-23
- ARBs 10,11,27-33,73-78
It is worth noting that DIUs have the greatest evidence of effectiveness regarding CV outcomes, with clear benefits for all types of events. In some situations, the indication of a certain group is reinforced, depending on the existing comorbidity. A BB can be considered the initial drug in certain situations, such as the presence of supraventricular arrhythmias, migraine, HF and CAD, and, in the last two conditions, the BB should be associated with other drugs.\textsuperscript{47,48}

The dosage should be adjusted to provide BP lowering to levels considered adequate for each case (therapeutic targets).\textsuperscript{1,2,8,79} If the therapeutic objective is not achieved with the initial monotherapy, there are three possible options:

- If the result is partial, but with no adverse effect, the dose of the drug used should be increased, and association with an antihypertensive drug of another group should be considered;
- When the therapeutic effect expected at the maximum dose recommended is not obtained or in the presence of adverse events, the following is recommended: replace the antihypertensive agent initially used, reduce its dosage, and add another antihypertensive agent of a different class or use another association of drugs;

---

\textbf{Figure 1 – Flowchart for the treatment of hypertension. CVR: cardiovascular risk; NPT: non-pharmacological treatment; DIU: diuretics; ACEI: angiotensin-converting-enzyme inhibitors; CCB: calcium-channel blockers; ARB: angiotensin-receptor blockers; BB: beta-blockers.}
• If the response is inappropriate, three or more drugs should be associated (Figure 1).

**Combination of drugs**

Most patients will need more than one drug to achieve BP targets. Therefore, patients with stage 1 AH and at high or very high CV risk or with CVD associated and those with stage 2 or 3 AH with or without other CVRF associated should be considered for drug combination (Figure 1). In addition, the association of two drugs at low doses for stage 1 hypertensive patients, even at low or intermediate CV risk, although not preferential, can be considered.

When choosing the drugs to be combined, antihypertensive agents sharing the same mechanism of action should be avoided, except for the association of thiazide DIUs and potassium-sparing DIUs. Loop DIUs should be reserved for individuals with GFR < 30 mL/min or severe edema. Associations with synergistic action provide better results (Figure 2).

**Particularities of the associations**

Less tested associations should be reserved for cases requiring a larger number of drugs;

The association of BB and DIU should be performed carefully for patients with glucose metabolism changes, because both drugs contribute to worsen them;

The association of ACEI and ARB is not recommended, because, in addition to showing no benefit in CV outcomes, it increases the risk for adverse effects; 13

Studies comparing directly the associations are scarce. A study has shown that the combination of ACEI and CCB, as compared to the association of ACEI and DIU, was more effective in lowering CV morbidity and mortality and the progression of kidney disease, for a similar reduction in BP, mainly in non-obese individuals. 81, 82

Combinations can be performed freely with separate drugs or in a fixed association (same galenic formulation). If, on the one hand, free combinations allow us to choose the dose of each component, on the other hand, the use of fixed associations favors adherence to treatment, because of the smaller number of tablets. 83

If BP control is not attained with two drugs, some decisions can be made:

• in case of partial result and no side effect, the dose of the initial combination can be increased, or one more antihypertensive agent of another drug class can be added;

• when the target is not achieved at the maximum dose recommended, or if adverse events occur, the combination should be replaced;

• if, at maximum doses, BP control is not attained, other antihypertensive drugs should be associated (Figure 1).
If a DIU was not the first choice and is not being used in the association of two drugs, it should be the third drug to be added. Its use potentiates the antihypertensive action of any initial drug. In cases of resistant AH (lack of BP control with at least three drugs at their maximum doses tolerated, one being a DIU), association of spironolactone is indicated. Sympatholytic drugs of central action (clonidine) or BBs can be an alternative to the fourth drug to be added, direct vasodilators being reserved for special cases and in association with a DIU and a BB.

References

1. Kanell WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275(20):1571-6.
2. Padwal R, Straus SE, McAlister FA. Evidence based management of hypertension. Cardiovascular risk factors and their impact on decision to treat hypertension: an evidence-based review. BMJ. 2001;322(7292):977-80.
3. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Keneson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14-26.
4. Daskalopoulou SS, Rabi DM, Zamke KB, Dasgupta K, Nerenberg K, Cloutier L, et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2015;31(5):549-68.
5. Lewington S, Clarke R, Qizilbash N, Petro R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13. Erratum in: Lancet. 2003;361(9362):1060.
6. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328(13):914-21.
7. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285-95.
8. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels overview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2296-304.
9. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects at patients different levels of cardiovascular risk overview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2305-14.
10. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs -- overview and meta-analyses. J Hypertens. 2015;33(2):195-211.
11. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens. 2015;33(7):1321-41.
12. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997;277(9):739-45.
13. Wright J, Lee CH, Chamber GK. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? CMAJ. 1999;161(1):25-32.
14. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64.
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcome in high-risk hypertensive patients to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97.
16. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):713-20.
17. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Trialists’ Collaboration. Lancet. 2000;356(9246):1955-64.
18. Hansson L, Lindholm LH, Ekborg T, Dahlof B, Lamek J, Schenten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354(9162):1299-33.
19. Stassen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Study. Lancet. 1997;350(9080):757-64.
20. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Mortality and morbidity in patients randomized to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366-72. Erratum in: Lancet. 2000;356(9228):514.
21. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syversten JQ, et al. Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356(9227):359-65.
22. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, et al. Health outcomes associated with calcium antagonists compared with other first line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000;356(9246):1949-54.
23. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al; ASCOT Investigators. Prevention of cardiovascular events with an angiotensin-II receptor antagonist for high-risk hypertensives: the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet. 2005;366(9489):895-906.
24. Hansson L, Lindholm LH, Niskanen L, Lamek J, Hedner T, Niklason A, et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality on hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet. 1999;353(9145):611-6.
25. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(13):145-53.

26. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;354(9197):1033-41. Erratum in: Lancet. 2001;358(9292):1556. Lancet. 2002;359(9323):2120.

27. Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention during Endpoint Reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995-1003.

28. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):1004-10.

29. Julius S, Kejdlensen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients in high cardiovascular risk treated with regimens based on valsartan and amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31.

30. Julius S, Weber MA, Kjeldsen SE, Mclmnes GT, Zanchetti A, Brunner HR, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006;48(3):389-91.

31. Oghara T, Nakao K, Fukui T, Fukiyama K, Oba K, et al; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlopidine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51(2):393-8.

32. Suzuki H, Kanno Y. Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients (E-COST). Hypertens Res. 2005;28(4):307-14. Erratum in: Hypertens Res. 2005;28(6):553.

33. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59.

34. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

35. Calberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364(9446):1545-53.

36. Lindholm LH, Calberg B, Samuelsson O. Should beta blocker remain a first choice in treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496):1545-53.

37. Bradley H, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for the use of beta-blockers as first-line therapy in hypertension? Systematic review and meta-analysis. J Hypertens. 2005;23(9):1639-44.

38. Parving HH, Brenner BM, McMurray JN, Zeeuwe D, Haffner SM, Solomon SD, et al; ALTITUDE Investigators. Cardio renal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-13.

39. The hypertension optimal treatment study (the HOT study). Blood Press. 1993;2(1):62-8.

40. Vongpatanasin W, Kario K, Atlas SA, Victor RG. Central sympathetic drugs. J Clin Hypertens (Greenwich). 2011;13(9):658-61.

41. Kaplan NM, Victor RG. Clinical hypertension. 11th ed. China: Wolters Kluwer; 2015. p. 198-262.

42. Wagner ML, Walters AS, Coleman RG, Hening WA, Graing K, Choknovety S. Randomized double-blind, placebo-controlled study of clonidine in restless leg syndrome. Sleep. 1996;19(1):52-8.

43. Bond WS. Psychiatric indications for clonidine. J Clin Psychopharmacol. 1986;6(2):81-7.

44. Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000;132(10):788-93.

45. Fedorak RN, Field M, Chang EB. Treatment of diabetic diarrhea with clonidine. Ann Intern Med. 1985;102(2):197-9.

46. Esler M, Dusley F, Jennings G, Debinski H, Lambert G, Jones P, et al. Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis. Ann Intern Med. 1992;116(6):446-55.

47. Holand M, Petersson K. Dana T. Drug class review on beta adrenergic blockers: Final Report [Internet]. [Cited in 2015 Jan 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25916632.

48. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al; Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341-62.

49. Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol. 2004;93(9A):3B-68.

50. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9(4):269-77.

51. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich). 2011;13(9):687-9.

52. Messerli FH. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am J Hypertens. 2002;15(7 Pt 2):945-975.

53. Elliott WJ, Bandari A. The role of calcium antagonists in stroke prevention. J Clin Hypertens (Greenwich). 2005;7(4 Suppl 1):5-8.

54. Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-vascular risk in hypertensive patients. Hypertension 2005; 46(4):637-42.

55. Oparil S, Bakir SE. Calcium antagonists in cardiovascular disease: clinical evidence from morbidity and mortality trials. Drugs. 2000;59 Spec No 2:25-37.

56. Rolls G. Calcium antagonist and beta blocker regimens found equally effective in hypertensive patients with coronary artery disease. Rep Med Guidel Outcomes Res. 2004;15(2):1, 5-6.

57. Sindone A, Erlich J, Perkovic V, Suriyani M, Newman H, Lee C, et al. ACEIs for cardiovascular risk reduction–have we taken our eye off the ball? Aust Fam Physician. 2013;42(9):634-8.

58. Vejakama P, Thakkinian J, Leattpronanond D, Ingpathl A, Ngarmucos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012;55(3):566-78.

59. Baram M, Kommuri A, Sellers SA, Cohn JR. ACE inhibitor-induced angioedema. J Allergy Clin Immunol Pract. 2013;1(5):442-5.

60. Ryan MJ, Tuttle KR. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury? Curr Opin Nephrol Hypertens. 2007;16(2):137-43.

61. Poliﬁka J. Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence. Birth Defects Res A Clin Mol Teratol. 2012;94(8):576-98.

62. Laube GF, Kemper MJ, Schubiger G, Neuhaus TJ. Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome. Arch Dis Child Fetal Neonatal Ed. 2007;92(5):F402-3.
63. Pfeifer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759-66.

64. Bremner BM, Cooper ME, de Zeeuw D, Keane WF, Mitchell WE, Parving HH, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.

65. Lewis EJ, Hunsicker LG, Clarke WR, Berk TH, Pohl MA, Lewis JB, et al; Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-60.

66. Parving HH, Lehnert H, Brochner-Mortensen J, Cornis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-8.

67. Müller DN, Derer W, Dechend R. Aliquisen-mode of action and preclinical data. J Mol Med (Berl). 2008;86(6):659-62.

68. Danser AH. (Pro)renin receptors: are they biologically relevant? Curr Opin Nephrol Hypertens. 2009;18(1):74-8.

69. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57(12):3297-306. Erratum in: Diabetes. 2009;58(3):770.

70. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD007066.

71. Dorsch MP, Gillegie BW, Ericksson SR, Bleske BE, Wieder AB. Chlorthalidone reduces cardiovascular event compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57(4):689-94.

72. Rouash GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110-7.

73. Tumbull F, Neal B, Pfeifer M, Kostis J, Algert C, Woodward M, et al; Blood Pressure Lowering Treatment Trialists Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25(5):951-8. Erratum in: J Hypertens. 2007;25(7):1524.

74. Reboldi G, Angelii F, Cavallini C, Gentile G, experimentation. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26(7):1282-9.

75. vanValk LC, Bertrand M, Akkermans KM, Brugs IJ, Fox K, Mourad IJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088-97.

76. Pfeifer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Magni G, et al; Valerian in Acute Myocardial Infarction Trial Investigators. Valerian, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-906. Erratum in: N Engl J Med. 2004 Jan 8;350(2):203.

77. Mann JF, Schmieder RE, McQueen M, Arigoni M, Schmieder RE, McQueen M, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-53.

78. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004;30(6):487-96.

79. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rococo MV, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-16.

80. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med. 2009;123(1):290-300.

81. Jamerson K, Weber MA, Bakris GL, Dahlol B, Pitt B, Shv V, et al; ACCOMPLISH Trial Investigators. Benazepril plusamlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28.

82. Bakris GL, Sarafi PA, Weir MR, Dahlol B, Pitt B, Jamerson K, et al; ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a pre-specified secondary analysis of a randomized controlled trial. Lancet. 2010;375(9721):1173-81.

83. Corsao G, Parodi A, Zampon A, Heiman F, Filippi A, Crucelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step: evidence from daily life practice. J Hypertens. 2010;28(7):1584-90.

84. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jankovsky J, et al. Addition of spironolactone in patients with resistant hypertension (ASPIRANT): a randomized double-blind, placebo-controlled trial. J Hypertens. 2011;57(4):1069-75. Erratum in: J Hypertens. 2011;57(7):721.

85. Bobrie G, Frank M, Azizi M, Peyrard S, Chatellier G, et al. Sequential nophron blockade vs. sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomised, open blinded endpoint study. J Hypertens. 2012;30(8):1656-64.

86. Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015;28(11):1376-85.